# Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

> **NCT00074867** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 29 (—)

## Conditions studied

- Ovarian Neoplasms
- Peritoneal Neoplasms
- Fallopian Tube Neoplasms

## Interventions

- **DRUG:** CP-547,632

## Key facts

- **NCT ID:** NCT00074867
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** —
- **Final completion:** 2004-09
- **Target enrollment:** 29 (—)
- **Last updated:** 2006-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00074867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00074867, "Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00074867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*